Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C25H27NO2 |
| Molecular Weight | 373.4874 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC\C(=C(\C1=CC=C(O)C=C1)C2=CC=C(OCCNC)C=C2)C3=CC=CC=C3
InChI
InChIKey=MHJBZVSGOZTKRH-OCOZRVBESA-N
InChI=1S/C25H27NO2/c1-3-24(19-7-5-4-6-8-19)25(20-9-13-22(27)14-10-20)21-11-15-23(16-12-21)28-18-17-26-2/h4-16,26-27H,3,17-18H2,1-2H3/b25-24+
| Molecular Formula | C25H27NO2 |
| Molecular Weight | 373.4874 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/27346789
https://www.ncbi.nlm.nih.gov/pubmed/21378205
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/27346789
https://www.ncbi.nlm.nih.gov/pubmed/21378205
(E)-Endoxifen is the E-isomer of (Z)-Endoxifen, potent selective estrogen receptor modulator. Endoxifen exists as the potently anti-estrogenic (Z)-isomer and the lesser known (E)-isomer. It is assumed that (E)-Endoxifen, structurally related to (E)-4-OH-tamoxifen, have similar pharmacological properties. The (E)-isomer is an impurity in (Z)-Endoxifen drug substance and increases under certain storage conditions. (E)-Endoxifen is identified as the primary degradant.
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1874 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28854070 |
160 mg 1 times / day steady-state, oral dose: 160 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ENDOXIFEN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
635 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28854070 |
160 mg single, oral dose: 160 mg route of administration: Oral experiment type: SINGLE co-administered: |
ENDOXIFEN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
15.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20981001 |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
ENDOXIFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
37.9 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28854070 |
160 mg 1 times / day steady-state, oral dose: 160 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ENDOXIFEN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
9.81 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28854070 |
160 mg single, oral dose: 160 mg route of administration: Oral experiment type: SINGLE co-administered: |
ENDOXIFEN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
801 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20981001 |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
ENDOXIFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
54.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28854070 |
160 mg single, oral dose: 160 mg route of administration: Oral experiment type: SINGLE co-administered: |
ENDOXIFEN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
52.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20981001 |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
ENDOXIFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
Sample Use Guides
Patients orally administered 4 mg/day or 8 mg/day endoxifen
Route of Administration:
Oral
The effects of tamoxifen, and its active metabolite endoxifen on hERG currents stably expressed in HEK cells were investigated using the whole-cell patch-clamp technique and an immunoblot assay. Tamoxifen and endoxifen inhibited hERG tail currents at -50mV in a concentration-dependent manner with IC50 values of 1.2 and 1.6μM, respectively. The steady-state activation curve of the hERG currents was shifted to the hyperpolarizing direction in the presence of endoxifen. The voltage-dependent inhibition of hERG currents by endoxifen increased steeply in the voltage range of channel activation.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 19:39:12 GMT 2023
by
admin
on
Fri Dec 15 19:39:12 GMT 2023
|
| Record UNII |
HB2U71MNOT
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
HB2U71MNOT
Created by
admin on Fri Dec 15 19:39:12 GMT 2023 , Edited by admin on Fri Dec 15 19:39:12 GMT 2023
|
PRIMARY | |||
|
114828-90-9
Created by
admin on Fri Dec 15 19:39:12 GMT 2023 , Edited by admin on Fri Dec 15 19:39:12 GMT 2023
|
PRIMARY | |||
|
3035980
Created by
admin on Fri Dec 15 19:39:12 GMT 2023 , Edited by admin on Fri Dec 15 19:39:12 GMT 2023
|
PRIMARY | |||
|
750182
Created by
admin on Fri Dec 15 19:39:12 GMT 2023 , Edited by admin on Fri Dec 15 19:39:12 GMT 2023
|
PRIMARY | |||
|
DTXSID70150869
Created by
admin on Fri Dec 15 19:39:12 GMT 2023 , Edited by admin on Fri Dec 15 19:39:12 GMT 2023
|
PRIMARY |